NCT00451672

Brief Summary

we propose that bromocriptine may be an alternative treatment of primary aldosteronism, both APA and BAH.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
25

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Jan 2007

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2007

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 22, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 23, 2007

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2007

Completed
Last Updated

March 23, 2007

Status Verified

December 1, 2006

First QC Date

March 22, 2007

Last Update Submit

March 22, 2007

Conditions

HyperaldosteronismHypertension

Keywords

aldosteronism, bromocriptin, hypertension

Outcome Measures

Primary Outcomes (1)

  • tumor size, blood pressure

Secondary Outcomes (1)

  • serum potassium, aldosterone, renine

Interventions

bromocriptineDRUG

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • y/o hyperaldosteronsim patients

You may not qualify if:

  • Malignancy
  • Bed-ridden
  • Psychological disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan Univserty Hospital

Taipei, Taiwan

RECRUITING

Related Publications (1)

  • Chang HW, Chu TS, Huang HY, Chueh SC, Wu VC, Chen YM, Hsieh BS, Wu KD. Down-regulation of D2 dopamine receptor and increased protein kinase Cmu phosphorylation in aldosterone-producing adenoma play roles in aldosterone overproduction. J Clin Endocrinol Metab. 2007 May;92(5):1863-70. doi: 10.1210/jc.2006-2338. Epub 2007 Feb 13.

    PMID: 17299068BACKGROUND

MeSH Terms

Conditions

HyperaldosteronismHypertension

Interventions

Bromocriptine

Condition Hierarchy (Ancestors)

Adrenocortical HyperfunctionAdrenal Gland DiseasesEndocrine System DiseasesVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

ErgotaminesErgot AlkaloidsAlkaloidsHeterocyclic CompoundsErgolinesHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-Ring

Study Officials

  • Kwan-Dun Wu, MD, PhD

    Internal Medicine, Natinal Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

  • Vin-Cent Wu, MD

    Internal Medicine, National Taiwan University Hospital

    STUDY DIRECTOR

Central Study Contacts

Kwan-Dun Wu, MD, PhD

CONTACT

+886-2-23562082walt-wu@yahoo.com.tw

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Expanded Access
Yes

Study Record Dates

First Submitted

March 22, 2007

First Posted

March 23, 2007

Study Start

January 1, 2007

Study Completion

December 1, 2007

Last Updated

March 23, 2007

Record last verified: 2006-12

Locations

TW(1)